HealthEquity, Inc
HQY
$98.54
+1.59%
HealthEquity, Inc. is a leading provider of technology-enabled services that empower consumers to make healthcare saving and spending decisions, primarily through tax-advantaged health savings accounts (HSAs) and other consumer-directed benefits like FSAs and HRAs. As a dominant player in the HSA administration market, HealthEquity differentiates itself through its integrated platform that combines payment processing, personalized benefit information, wellness incentives, and investment advisory services. The current investor narrative centers on the company's consistent revenue growth and margin expansion, driven by rising HSA adoption and increasing account balances, while recent quarterly results have beaten expectations, reinforcing confidence in its long-term growth trajectory despite a competitive healthcare IT landscape.…
HQY
HealthEquity, Inc
$98.54
Related headlines
Investment Opinion: Should I buy HQY Today?
Based on the data, HQY is rated a Buy. The consensus is Strong Buy with an average target of $118.53, implying 23% upside. The thesis is that the company's margin expansion and forward earnings growth will drive the stock higher, despite modest revenue growth.
Sign up to view all
HQY 12-Month Price Forecast
The AI assessment is bullish, driven by attractive forward valuation and strong profitability. However, confidence is medium due to decelerating revenue growth and recent price volatility. The stock is likely to appreciate if growth stabilizes, but a downgrade to neutral would occur if revenue growth falls below 5% or margins contract.
Wall Street consensus
Most Wall Street analysts maintain a constructive view on HealthEquity, Inc's 12-month outlook, with a consensus price target around $119.00 and implied upside of +20.8% versus the current price.
Average Target
$119.00
0 analysts
Implied Upside
+20.8%
vs. current price
Analyst Count
—
covering this stock
Price Range
$105 - $142
Analyst target range
HealthEquity is covered by 15 analysts, with a consensus recommendation of 'Strong Buy' (mean rating of 1.33). The average target price is $118.53, implying approximately +23% upside from the current price of $96.37. The analyst sentiment is overwhelmingly bullish, with no Hold or Sell ratings, and recent actions include upgrades from BMO Capital (to Outperform) and reaffirmations from RBC Capital and Barrington Research. The target price range spans from $105.00 (low) to $135.00 (high), indicating a wide spread of 28.6% between the low and high targets, reflecting uncertainty about the pace of HSA adoption and competitive dynamics. The high target of $135 assumes continued strong growth and margin expansion, while the low target of $105 suggests a more conservative scenario with potential headwinds from regulatory changes or increased competition. Overall, the bullish consensus and recent earnings beat support a positive outlook, but the wide target range highlights the need for investors to monitor execution closely.
Bulls vs Bears: HQY Investment Factors
HealthEquity presents a mixed picture: strong profitability, a solid balance sheet, and bullish analyst sentiment are offset by decelerating revenue growth and a rich trailing valuation. The bull case rests on margin expansion and forward earnings growth, while the bear case centers on growth slowdown and potential multiple compression. Currently, the evidence slightly favors the bulls due to the strong Q1 beat and low forward PE, but the key tension is whether revenue growth can re-accelerate to justify the premium. If growth remains in the single digits, the stock may struggle to reach analyst targets.
Bullish
- Strong Q1 FY2027 beat: Revenue of $354.6M grew 7.2% YoY, accelerating from the prior quarter's $334.6M, and EPS of $0.82 beat estimates. This marks the second consecutive quarter of revenue acceleration, signaling improving momentum.
- Expanding margins: Gross margin jumped to 72.3% in Q1 FY2027 from 62.4% in Q3 FY2026, and net margin improved to 19.6% from 16.0%. Operating leverage is driving profitability higher, with operating margin at 29.0%.
- Analyst consensus Strong Buy: All 15 analysts rate HQY a Buy, with a mean rating of 1.33 and an average target of $118.53, implying ~23% upside. No Hold or Sell ratings, reflecting high conviction in the growth story.
- Undervalued on forward earnings: Forward PE of 17.6x is below the industry average, while PEG ratio of 0.27 suggests the stock is cheap relative to its growth rate. This valuation gap could close as earnings grow.
Bearish
- Revenue growth decelerating: Despite the Q1 beat, YoY growth of 7.2% is down from 10.1% in Q2 FY2026 and 12.6% in Q1 FY2026. The company is growing slower than its historical pace, which may limit multiple expansion.
- High trailing valuation: Trailing PE of 34.3x is above the industry average, and the stock trades at 5.6x sales. If growth disappoints, the multiple could compress, leading to a de-rating.
- Recent price volatility: The stock dropped 11.4% on August 27, 2026, following Q2 earnings, despite beating estimates. This suggests investors are sensitive to any signs of slowing growth or guidance concerns.
- Dependence on HSA adoption: Revenue is tied to HSA account growth and interest rates. If HSA adoption slows or interest rates decline, financial service revenue could suffer, impacting overall growth.
HQY Technical Analysis
HealthEquity's stock has demonstrated a robust long-term uptrend, with a 1-year price change of +9.15% and a 6-month change of +25.99%, positioning the current price of $96.37 at approximately 89.5% of its 52-week range (between $72.76 low and $107.62 high). This proximity to the high end suggests strong momentum, though it also implies the stock may be approaching overbought conditions, warranting caution for new entries. The stock's beta of 0.233 indicates significantly lower volatility than the broader market, making it a defensive growth holding.
Beta
0.23
0.23x market volatility
Max Drawdown
-30.6%
Largest decline past year
52-Week Range
$73-$108
Price range past year
Annual Return
+10.9%
Cumulative gain past year
| Period | HQY Return | S&P 500 |
|---|---|---|
| 1m | -5.6% | +1.0% |
| 3m | +14.5% | +1.1% |
| 6m | +25.8% | +13.8% |
| 1y | +10.9% | +19.5% |
| ytd | +8.2% | +12.2% |
Bobby - Your AI Investment Partner
Get real-time data, AI-driven personalized investment analysis to make smarter investment decisions
HQY Fundamental Analysis
HealthEquity's revenue trajectory remains solid, with the most recent quarter (Q1 FY2027, ending April 30, 2026) reporting revenue of $354.6 million, up 7.2% year-over-year, and accelerating from the prior quarter's $334.6 million. The multi-quarter trend shows consistent growth, with revenue rising from $300.4 million in Q3 FY2025 to $354.6 million in Q1 FY2027, driven by growth in service revenue ($122.9 million) and financial service revenue ($174.3 million). The company's profitability is robust, with net income of $69.4 million in the latest quarter, representing a net margin of 19.6%, and gross margin expanding to 72.3% from 62.4% in the prior quarter, reflecting operational leverage and a favorable revenue mix. HealthEquity maintains a healthy balance sheet with a debt-to-equity ratio of 0.48, a current ratio of 3.27, and strong free cash flow of $97.2 million in the latest quarter, enabling it to fund growth internally while returning capital to shareholders through buybacks.
Quarterly Revenue
$354641000.0B
2026-04
Revenue YoY Growth
+7.2%
YoY Comparison
Gross Margin
72.3%
Latest Quarter
Free Cash Flow
$487637000.0B
Last 12 Months
Revenue & Net Income Trends (2 Years)
Revenue Breakdown
Open an Account, get $2 TSLA now!
Valuation Analysis: Is HQY Overvalued?
Given HealthEquity's positive net income, the PE ratio is the primary valuation metric. The trailing PE stands at 34.3x, while the forward PE is 17.6x, implying the market expects significant earnings growth, consistent with the company's PEG ratio of 0.27. Compared to the industry average, HealthEquity trades at a premium on a trailing basis but at a discount on a forward basis, reflecting its superior growth prospects and profitability. Historically, the stock's PE has ranged from negative values in 2022 to over 300x in late 2024, with the current trailing PE of 34.3x near the lower end of its historical band, suggesting the stock is reasonably valued relative to its own history, especially given its improving margins and cash flow generation.
PE
34.3x
Latest Quarter
vs. Historical
Low-End
5-Year PE Range 25x~142x
vs. Industry Avg
N/A
Industry PE ~N/A*
EV/EBITDA
16.5x
Enterprise Value Multiple
Investment Risk Disclosure
Financial risks include a high debt-to-equity ratio of 0.48, which, while manageable, could become a burden if interest rates rise. The company's net margin of 19.6% is solid, but it is dependent on continued operational leverage; any margin contraction could hit earnings. Revenue concentration in HSA-related services makes the company vulnerable to regulatory changes affecting HSA contribution limits or tax advantages. Cash flow is strong, but the company has a history of acquisitions, which could lead to integration risks and goodwill impairment.